➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Moodys
Express Scripts
Medtronic
Dow

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for CERC-301


Email this page to a colleague

« Back to Dashboard

What is the drug development status for CERC-301?

CERC-301 is an investigational drug.

There have been 7 clinical trials for CERC-301. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2015.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Cerecor Inc, Yale University, and Indiana University.

There are ten US patents protecting this investigational drug and one hundred and forty international patents.

Recent Clinical Trials for CERC-301
TitleSponsorPhase
Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung InjuryAevi Genomic Medicine, LLC, a Cerecor companyPhase 2
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?Cerecor IncPhase 2
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?National Institute on Drug Abuse (NIDA)Phase 2

See all CERC-301 clinical trials

Clinical Trial Summary for CERC-301

Top disease conditions for CERC-301
Top clinical trial sponsors for CERC-301

See all CERC-301 clinical trials

US Patents for CERC-301

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CERC-301   Get Started Free Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited (Grand Cayman, KY)   Get Started Free
CERC-301   Get Started Free Class of mu-opioid receptor agonists THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, NY)   Get Started Free
CERC-301   Get Started Free Compounds, compositions and methods CERECOR, INC. (Baltimore, MD) MERCK SHARP & DOHME CORP. (Rahway, NJ)   Get Started Free
CERC-301   Get Started Free 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists RUGEN HOLDINGS (CAYMAN) LIMITED (Grand Cayman, KY)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CERC-301

Drugname Country Document Number Estimated Expiration Related US Patent
CERC-301 Argentina AR100733 2034-06-04   Get Started Free
CERC-301 Australia AU2015271719 2034-06-04   Get Started Free
CERC-301 Canada CA2950285 2034-06-04   Get Started Free
CERC-301 China CN106795163 2034-06-04   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Medtronic
Express Scripts
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.